Literature DB >> 20428632

Outbreak of resistant Acinetobacter baumannii- measures and proposal for prevention and control.

Roberta Maia de Castro Romanelli1, Lenize Adriana de Jesus, Wanessa Trindade Clemente, Stella Sala Soares Lima, Edna Maria Rezende, Rosane Luiza Coutinho, Ricardo Luiz Fontes Moreira, Francelli Aparecida Cordeiro Neves, Nelma de Jesus Brás.   

Abstract

Acinetobacter baumannii colonization and infection, frequent in Intensive Care Unit (ICU) patients, is commonly associated with high morbimortality. Several outbreaks due to multidrug-resistant (MDR) A. baumanii have been reported but few of them in Brazil. This study aimed to identify risk factors associated with colonization and infection by MDR and carbapenem-resistant A. baumannii strains isolated from patients admitted to the adult ICU at HC/UFMG. A case-control study was performed from January 2007 to June 2008. Cases were defined as patients colonized or infected by MDR/carbapenem-resistant A. baumannii, and controls were patients without MDR/carbapenem-resistant A. baumannii isolation, in a 1:2 proportion. For statistical analysis, due to changes in infection control guidelines, infection criteria and the notification process, this study was divided into two periods. During the first period analyzed, from January to December 2007, colonization or infection by MDR/carbapenem-resistant A. baumannii was associated with prior infection, invasive device utilization, prior carbapenem use and clinical severity. In the multivariate analysis, prior infection and mechanical ventilation proved to be statistically significant risk factors. Carbapenem use showed a tendency towards a statistical association. During the second study period, from January to June 2008, variables with a significant association with MDR/carbapenem-resistant A. baumannii colonization/infection were catheter utilization, carbapenem and third-generation cephalosporin use, hepatic transplantation, and clinical severity. In the multivariate analysis, only CVC use showed a statistical difference. Carbapenem and third-generation cephalosporin use displayed a tendency to be risk factors. Risk factors must be focused on infection control and prevention measures considering A. baumanni dissemination.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20428632     DOI: 10.1590/S1413-86702009000500005

Source DB:  PubMed          Journal:  Braz J Infect Dis        ISSN: 1413-8670            Impact factor:   1.949


  4 in total

1.  Increase of carbapenem-resistant Acinetobacter baumannii infection in acute care hospitals in Taiwan: association with hospital antimicrobial usage.

Authors:  Chiu-Hsia Su; Jann-Tay Wang; Chao A Hsiung; Li-Jung Chien; Cheng-Liang Chi; Hui-Tzu Yu; Feng-Yee Chang; Shan-Chwen Chang
Journal:  PLoS One       Date:  2012-05-21       Impact factor: 3.240

2.  Resistance patterns of multidrug resistant Acinetobacter baumannii in an ICU of a tertiary care hospital, Malaysia.

Authors:  Sivakami Janahiraman; Muhammad Nazri Aziz; Fan Kee Hoo; Hon Shen P'ng; Yang Liang Boo; Vasudevan Ramachandran; Ahmad Fuad Shamsuddin
Journal:  Pak J Med Sci       Date:  2015 Nov-Dec       Impact factor: 1.088

3.  Immunogenicity of Cork and Loop Domains of Recombinant Baumannii acinetobactin Utilization Protein in Murine Model.

Authors:  Hamid Esmaeilkhani; Iraj Rasooli; Masoomeh Hashemi; Shahram Nazarian; Fatemeh Sefid
Journal:  Avicenna J Med Biotechnol       Date:  2019 Apr-Jun

4.  Predictive factors for sepsis by carbapenem resistant Gram-negative bacilli in adult critical patients in Rio de Janeiro: a case-case-control design in a prospective cohort study.

Authors:  Elisangela M Lima; Patrícia A Cid; Debora S Beck; Luiz Henrique Z Pinheiro; João Pedro S Tonhá; Marcio Z O Alves; Newton D Lourenço; Roberto Q Santos; Marise D Asensi; José Aurélio Marques; Carolina S Bandeira; Caio Augusto S Rodrigues; Saint Clair S Gomes Junior; Marisa Z R Gomes
Journal:  Antimicrob Resist Infect Control       Date:  2020-08-14       Impact factor: 4.887

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.